Eledon Trial Achieves 100% Insulin Independence in Tegoprubart Islet-Transplant Study
ELDN•Eledon Pharmaceuticals reported that all evaluable patients in its islet-transplant trial combining tegoprubart with donor islets achieved insulin independence, demonstrating a 100% success rate. The result positions Eledon ahead in the cell therapy field as rivals like Avaí Bio finalize a GMP Master Cell Bank for their alpha-Klotho program.
1. Islet-Transplant Trial Results
Eledon Pharmaceuticals announced that in its islet-transplant trial pairing tegoprubart with donor islets, all evaluable patients reached insulin independence, marking a 100% success rate in this early-stage study.
2. Tegoprubart Therapy and Manufacturing
Tegoprubart is designed to modulate immune response and support donor islet engraftment; the complete insulin independence outcome bolsters confidence in Eledon’s ability to scale production and meet regulatory standards for commercial manufacturing.
3. Competitive Landscape in Cell Therapy
Eledon’s positive trial data coincide with Avaí Bio and Austrianova’s completion of a GMP-grade Master Cell Bank for alpha-Klotho anti-aging cells, highlighting a competitive race among microcaps to secure validated, manufacturable cell therapy platforms.
